Hodgkin Lymphoma Flashcards

1
Q

Two types of HL

A

**I. CHL **(95% of HL, 2 peaks in age, EBV associated, IMPT: CD15+, CD30+, CD45-)
* Nodular Sclerosing (70%)
* Mixed cellularity
* Lymphocyte rich
* Lymphocyte depleted

II. Non-CHL (5% of HL, 30-50 yo males, LP cells, IMPT: CD15-, CD30- and CD45+)
* Nodular lymphocyte predoninant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Treatment of HL

A

PDL-1 Inhibitors:

  • Pembroluzumab
  • Nivolumab
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is true of all the four subtypes of

CHL?

A
  • derived from B cells
  • mononuclear Hodgkin cells and multinucleated RS cells present in all
    • reduced expression of B cell antigens
      • CD20, CD79a and PAX5
    • positive for: CD15 and CD30
  • variable EBV association (subtype specific)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the 4 subtypes of

CHL?

A
  • Nodular Sclerosis
  • Lymphocyte rich
  • Mixed cellularity
  • Lymphocyte depleted
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the Syncytial variant of

Nodular Sclerosing CHL?

A
  • lacunar cells form cohesive nests in the centres of the nodules
  • necrosis may or may not be present
    • if prominent should consider this variant
  • may think this is Anaplastic large cell lymphoma
  • PAX5 positive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Features of NS CHL

A
  • Nodules
  • Mediastinum and bulky disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What two subtypes of CHL are often

associated with EBV infection?

A
  • Mixed cellularity CHL
  • Lymphocyte depleted CHL

Note: NLPHL is only rarely associated with EBV infection (<5%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Features of MC CHL

A
  • Diffuse
  • Peripheral LNs and spleen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Features of LR CHL

A
  • Nodular
  • Peripheral LNs
  • B-Sx = rare
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Features of LD CHL

A
  • > HRS : Lymphocytes
  • Intra-abdominal LNs and Extranodal disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

DDx for HRS cells

6

A
  1. HL
  2. EBV+ DLBCL
  3. 1’ DLBCL of CNS
  4. 1’ mediastinal LBCL
  5. 1’ Effusion lymphoma
  6. TCHR LBCL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

DDx for CD30+ lymphomas

HL, BCL(5), TCL(5)

A

I. HL

II. BCL
* Anaplastic variant of DLBCL
* Lymphomatoid granulomatosis
* PBL
* ALK+ LBCL
* 1’ effusion lymphoma

III. TCL
* ATCL
* Extranodal NK/TCL
* Enteropathy ass. TCL
* PTCL, NOS
* ALCL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the morphology of Classic

Reed-Sternberg Cells?

A
  • large with abundant and slightly basophilic cytoplasm
  • have at least 2 nuclear lobes and 2 nuclei
    • can have more than this
  • nuclei are large, rounded contours
  • prominent, irregular nuclear membrane
  • pale chromatin, eosinophlic nucleolus
    • perinuclear halo
    • 2 prominent nucleoli in 2 separate nuclei in one cell
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the EBV expression of HS cells

of CHL ?

A
  • EBV infected cells express LMP1 and EBNA1
    • no expression of EBNA2
    • this is characteristic of type II EBV infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Hodgkin lymphomas generally affect which

organs and what is a common feature of

most of them?

A
  • usually affect Lymph Nodes
  • variable mixture of associated, non-neoplastic inflammatory cells
  • sometimes associated with variable fibrosis (thick band like)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the 2 types of

Hodgkin’s Lymphomas?

A
  • Nodular lymphocyte predominant (NLPHL)
  • Classic Hodgkin Lymphoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Which HL is the most common type and

what age groups is it often seen in?

A
  • Classic Hodgkin Lymphoma
    • 90% of all HL
  • Two peaks
    • 15-35 years old
    • late life
  • Has different subtypes that fall into these categories
18
Q

How does HL (both types, general) present

clinically?

A
  • peripheral lymphadenopathy
    • usually localized to 1-2 lymph nodes
    • generally cervical
    • NLPHL prefers peripheral lymph nodes
  • B symptoms
    • fever, drenching night sweats, weight loss
    • NLPHL does not present with B symptoms, in fact it is usually asymptomatic
19
Q

At what stage of B cell maturation are

Hodgkin/R-S cells derived from?

A
  • > 98% of cases are neoplastic B cells
  • derived from mature B cells of the germinal centre stage
  • clonal IG genes
20
Q

What are the 4 subtypes of

Classical Hodgkin’s Lymphoma?

A
  • Nodular Sclerosis Hodgkin Lymphoma
  • Lymphocyte rich CHL
  • Mixed Cellularity CHL
  • Lymphocyte depleted CHL
21
Q

What age group is preferentially affected

by Nodular Lymphocyte Predominant HL?

A
  • generally 4th-5th decade
  • also common in children
  • M > F
22
Q

CHL subtypes tend to have a male predominance, with the exception of which subtype?

A
  • Nodular sclerosing HL
    • slight female predominance
23
Q

What is the morphology of the Hodgkin cell

and the Mummified Hodgkin cell?

A
  • smudgy large nuclei (may be slightly eosinophilic)
  • can be anaplastic and confused with ALCL
24
Q

What is the immunophenotype of the HS

of CHL?

A
  • CD15 and CD30- membranous pattern with accentuation in the Golgi region
  • PAX5
    • weaker than reactive B cells (IMP)
  • IRF4/MUM1 - strongly positive
  • CD20
    • positive in 30% of cases
  • CD79a
    • not often expressed
  • CD45 and CD68 - negative
25
What is the expression of OCT2 and BOB1 in CHL HS cells?
* absence of the transcription factor (OCT2) and its cofactor (BOB1) Note: EMA is also negative in most cases
26
How can CHL lymphoma be mistaken for ALCL and what IHC helps differentiate the two well?
* if the CHL is rich in neopastic cells it can morphologically resemble ALCL * IHC * CHL = PAX5 (+) * EMA and ALK protein (-) * Detection of EBV (LMP1) favors CHL over ALCL as well
27
What is one of the most difficult d/d with CHL to differentiate?
* DLBCL with anaplastic morphology and CD30 (+) cells * especially if it is within the mediastinum
28
What is the IHC findings of NLPHL?
* very different from CHL, preserve B cell programming * Positive: * CD20, CD79a, PAX5 * OCT2, BOB1 * Negative: * CD30 (can have patchy, weak +) * CD15 * EMA
29
In what subset of patients would you more likely see IgD expression by the LP cells in NLPHL?
* IgD expression is usually seen in the LP cells of young males
30
What T lymphocytes are found predominantly in the cellular milieu of HL?
* T helper 2 cells * thought to be a result of the abnormal cytokine production of CHL cells
31
What is the normal counterpart to the HRS cells of CHL?
* clonal and Germinal center B cell derived * based on IG studies Note: LP cells are clonal expansions of GCB cells as well but they have the classic immunophenotype
32
What is the EBV expression/infection pattern in the various types of HL?
* Highest: * MCCHL * LDCHL * Lowest: * NLPHL Note: NSCHL shows an intermediate range of EBV positivity IMP: HIV and in resource poor countries EBV + is almost 100%
33
What medications are part of the ABVD protocol to treat CHL?
* Doxorubicin * Bleomycin * Vinblastine * Dacarbazine
34
What medications are included in the escalated BEACOPP treatment protocol?
* Bleomycin * Etoposide * Doxorubicin * Cyclophosphamide * Vincristine * Procarbazine * Prednisone
35
What is the current prognosis of CHL with modern treatments?
* \>85% of cases of CHL are curable Note: in advanced stage disease the International Prognostic Index score correlates with prognosis
36
What is a new drug that has been approved for treatment of relapsed/refractory CHL?
* Brentuximab vedotin * CD30 directed antibody Note: anti-PD1 antibodies have also been investigated and have promising results
37
What has been shown with tumor infiltrating CD68+, histiocytes in CHL?
* a high content of macrophages correlated with reduced progression-free survival * also a high content is a feature of some aggressive forms of CHL like lymphocyte-depleted subtype
38
Treatment approach in CHL
**PET** adapted regimens with **ABVD/BEACOPP** New: BEACOP-Dac/BV-AVD/N-AVD **Ann Arbor:** **I. Early (I/II)** * Prognosis (GHSC) = Mediastinal/Bulky, ESR, Estra-Nodal and Nr of LN) * **Favourable:** 2x ABVD & RT or 4-6x ABVD * **Advance:** 4x ABVD & RT or 4-6 ABVD **II. Late (III/IV)** * **RATHL** = 2x ABVD then PET (Deauville score) * 1-3 (PET neg) = ABVD x6 * > 3 (PET pos) = BEACOPP x6 or escBEACOPP x4 * **GHSG** = 2x BEACOPP the PET * PET neg = 2x esc BEACOPP * PET pos = 4x esc BEACOPP
39
PET Deauville Score?
**Nodal Uptake:** * 0 = No uptake * 1 = Uptake but < than heart * 2 = Uptake > than heart but < than liver * 3 = Uptake > than liver * 4 = +++ > than liver
40
Treatment of NLPHL
Ann Arbor stage **I. Early:** * Surgery * RT * W&W **II. > 2 sites or Late:** * W&W * R-CVP/R-ABVD * R-CHOP * R
41